Treatment with the recently approved oral, selective JAK-1 inhibitor upadacitinib (Rinvoq, AbbVie) resulted in significant improvements in various patient-reported outcomes among individuals with rheumatoid arthritis who have had inadequate responses to biologic DMARDs, researchers report in Arthritis Research & Therapy.
Psoriatic arthritis patients with moderate disease activity were more likely to reach treatment targets or low disease activity at week 52 with apremilast (Otezla, Celgene) than patients with high disease activity, researchers report in the January 7 issue of Arthritis Care and Research.
Patients and doctors still haven't fully invested in the use of biosimilars, despite a steady rise in the cost of biologics, shows a new report by Harvard researchers.
Turkish researchers are reporting the results of small study that shows too much vitamin D may be associated with the severity of in disease ankylosing spondylitis patients. Learn more about this and other recent findings from spondylarthritis research in today's news roundup.
Updated treatment guidelines for hand, hip and knee osteoarthritis have been issued. In this slideshow, we highlight recommendations for the use (or not) of drug and nondrug treatments. These include strong recommendations for standard treatment options, such as weight loss and Tai Chi, and strong recommendations against treatments with pharmacologicals, such as glucosamine and chondroitin sulfate (except for hand osteoarthritis). Learn more in this slideshow.
The American College of Rheumatology (ACR), in partnership with the Arthritis Foundation, has issued treatment guidelines for osteoarthritis of the hand, hip and knee. This is the first update since 2012.
In patients with ankylosing spondylitis receiving treatment with non‐steroidal anti‐inflammatory drugs (NSAIDs), timely therapeutic strategies should be implemented in order to manage gastrointestinal risk, say researchers recently writing in the International Journal of Rheumatic Disease.
Secukinumab (Cosentyx, Novartis) provided sustained improvements through five years in the signs and symptoms of psoriatic arthritis with no new safety signals, say researchers recently writing in ACR Open Rheumatology.
In a review published last month in Autoimmunity Reviews, British researchers outline factors physicians should consider when contemplating tapering biologic therapies in patients with inflammatory arthritis. How best to wean patients from biologic therapy is an issue that comes up more frequently these days as patients increasingly achieve remission or low disease activity. In this slideshow, we highlight considerations physicians may want to consider in treating these patients.
A 62-year-old woman complained to her doctor about joint pain in her fingers. The joints in her fingers were warm, tender, and slightly swollen. Can you diagnose this patient?
In this slideshow, we feature the lupus stories that resonated most with our readers in 2019: Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
In this slideshow, we revisit some of our most popular stories of the year: Insurers weigh in on step therapy, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis, conflicting studies were published on treatments that may (or, may not) cause deadly infections, among others.
Frailty score, age and C-reactive protein (CRP) are associated with mortality in elderly patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, say researchers writing in Rheumatology this fall.
The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids, to fulfil an unmet medical need for these rare and serious diseases in children.
Nearly one third of patients with systemic lupus erythematosus use prescription opioids, with around two thirds of those using opioids for more than a year, while emergency department use is associated with increased prescription opioid use, say researchers writing in Morbidity and Mortality Weekly Report in Septmeber.